Adakveo: An FDA-indicated treatment for sickle cell disease

Adakveo (crizanlizumab-tmca) from Novartis is FDA indicated for reducing the number of vasoocclusive crises in people aged 16 years and older with sickle cell disease.

Novartis describes it as “the first and only once monthly medication to reduce the number of pain crises in sickle cell disease.”

The drug works by inhibiting selectin, a group of carbohydrate-binding transmembrane molecules associated with cells clinging together, which results in vaso-occlusive crisis


Read more
  • 0